Saturday 17 October 2026
Export NNVC’s income statement to Excel — free account
NanoViricides, Inc.
NNVC Healthcare Biotechnology
In the quarter to June 2026, EPS grew 24.1% and free cash flow fell 23.9%, each against the same quarter a year earlier.
1.38
0.01
+0.73%
Follow NNVC
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (101.46%) | (89.97%) | (77.53%) | (94.03%) |
+8 more TTM periods Free account |
|
| (87.91%) | (79.91%) | (69.79%) | (80.86%) | ||
ROIC |
(88.16%) | (86.02%) | (88.61%) | (84.94%) | |
Return on Tangible Assets |
(98.15%) | (91.51%) | (77.33%) | (118.48%) | |
Free Cash Flow per Share |
(0.39) | (0.34) | (0.37) | (0.44) | |
Free Cash Flow |
(7.78) | (7.37) | (7.43) | (7.57) | |
Capital Expenditures |
(0.08) | (0.09) | (0.09) | (0.09) | |
| Other line items | |||||
Cash ROIC |
(67.79%) | (59.60%) | (45.81%) | (91.23%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.94 | 0.90 | 0.88 | 0.92 | |
Depreciation/Fixed assets |
0.08 | 0.09 | 0.09 | 0.10 | |
Capex/Depreciation |
(0.16) | (0.17) | (0.15) | (0.14) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.38) | (0.34) | (0.37) | (0.44) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 30 Sep 2026